Treatment of Guillain-Barre syndrome with interferon-β

Lancet

Volumn 352, Issue 9125, 1998, Pages 368-369

  Créange, Alain ^a   Lerat, Hervé ^b   Meyrignac, Christian ^b   Degos, Jean Denis ^b   Gherardi, Romain K ^b   Cesaro, Pierre ^b  

^a HENRI MONDOR HOSPITAL   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT BETA INTERFERON;

ACTION POTENTIAL; ADULT; ARTICLE; CASE REPORT; DENERVATION; DIARRHEA; GUILLAIN BARRE SYNDROME; HUMAN; MALE; MUSCLE WEAKNESS; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; SERODIAGNOSIS; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0032146350     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)60466-7     Document Type: Article

References (5)

1. 1 Vriesendorp FJ, Flynn RE, Khan M, Pappolla MA, Brod SA. Oral administration of type I interferon β modulates the course of experimental allergic neuritis. Autoimmunity 1996; 24: 157-65.
2. 2 Choudhary PP, Thompson N, Hughes RAC. Improvement following interferon beta in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol 1995; 242: 252-53.
3. 3 Hughes RAC. Modulating the immune response in demyelinating diseases. J Neurol Neurosurg Psychiatry 1998; 64: 148.
4. 4 Rees JH, Soudain SE, Gregson NA, Hughes RAC. Campylobacter jejuni infection and Guillain-Barré syndrome. N Engl J Med 1995; 333: 1374-79.
5. 5 Dyck PJ, Sherman WR, Hallcher LM, et al. Human diabetic endoneurial sorbital, fructose and myo-inositol related to sural nerve morphometry. Ann Neurol 1980; 8: 590-96.